Craft
Albumedix

Albumedix

Revenue

£26.1 M

FY, 2018

Albumedix Summary

Company summary

Overview
Albumedix develops bio-therapeutics formulations for advanced drug and vaccine formulation intended to improve therapies for people with serious diseases. It offers recombumin, drug and vaccine stabilization, cell therapy formulation, drug conjugates, enabling the medical sector to formulate drugs for treatment of diseases.
Type
Private
Status
Active
Founded
2016
HQ
Nottinghamshire, GB | view all locations
Website
https://albumedix.com/
Cybersecurity rating
Sectors

Key people

  • Phil Morton

    Phil Morton, Chief Technology Officer

  • Jonas S. Møller

    Jonas S. Møller, Chief Executive Officer

    • Stuart Woodward

      Stuart Woodward, Chief Manufacturing Officer

      • Charlotte Diamond

        Charlotte Diamond, General Counsel and Company Secretary

        LocationsView all

        2 locations detected

        • Nottinghamshire, England HQ

          United Kingdom

          59 Castle Blvd

        • Nottingham, England

          United Kingdom

          Mabel St

        Albumedix Financials

        Summary financials

        Revenue (FY, 2018)
        £26.1M
        Net income (FY, 2018)
        £5.0M
        Cash (FY, 2018)
        £10.5M
        EBIT (FY, 2018)
        £5.5M

        Footer menu